Anticraving medications for relapse prevention: A possible new class of psychoactive medications

被引:290
作者
O'Brien, CP [1 ]
机构
[1] Univ Penn, Treatment Res Ctr, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA
关键词
D O I
10.1176/appi.ajp.162.8.1423
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Psychiatrists have gradually developed a list of medications that are effective in the treatment of addictive disorders. Although alcoholism has received the most attention, nicotine, heroin, and cocaine have all been shown to be influenced by heredity. Of course, the immediate goal is the reduction of drug craving and the prevention of relapse to compulsive drug taking. A medication that can aid in the maintenance of the opiate-free state is naltrexone, a specific opiate antagonist. Naltrexone is also a good example of an anticraving medication used in the treatment of alcoholism. Clinicians currently have two types of medication to aid in the treatment of tobacco use disorder, arguably the most important addiction. Bupropion propion and nicotine replacement can be given in a coordinated fashion to provide the best available results. At present, no medication is approved by the Food and Drug Administration for the indication of cocaine addiction. Recently, however, five different medications, already approved for other purposes, have been found to be effective among cocaine addicts. Despite clinical trials that show benefit, anti-craving medications are not well known and are underused by clinicians. Addiction is a heterogeneous condition, with variability in reactivity to the drug of abuse and to the medications available to treat it. Recent developments in pharmacogenetics may result in improved selection of medications based on genotype.
引用
收藏
页码:1423 / 1431
页数:9
相关论文
共 72 条
[1]  
Allen JP, 1997, J STUD ALCOHOL, V58, P7
[2]   ALTERATION OF ETHANOL SELF-ADMINISTRATION BY NALTREXONE [J].
ALTSHULER, HL ;
PHILLIPS, PE ;
FEINHANDLER, DA .
LIFE SCIENCES, 1980, 26 (09) :679-688
[3]   Comparative Epidemiology of Dependence on Tobacco, Alcohol, Controlled Substances, and Inhalants: Basic Findings From the National Comorbidity Survey [J].
Anthony, James C. ;
Warner, Lynn A. ;
Kessler, Ronald C. .
EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, 1994, 2 (03) :244-268
[4]  
Anton RF, 1996, ARCH GEN PSYCHIAT, V53, P225
[5]  
Anton RF, 1999, AM J PSYCHIAT, V156, P1758
[6]   Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors [J].
Arnone, M ;
Maruani, J ;
Chaperon, F ;
Thiebot, MH ;
Poncelet, M ;
Soubrie, P ;
LeFur, G .
PSYCHOPHARMACOLOGY, 1997, 132 (01) :104-106
[7]  
BABOR TF, 1992, ARCH GEN PSYCHIAT, V49, P599
[8]   THE GENETICS OF ALCOHOLISMS AND RELATED DISORDERS [J].
BOHMAN, M ;
CLONINGER, R ;
SIGVARDSSON, S ;
VONKNORRING, AL .
JOURNAL OF PSYCHIATRIC RESEARCH, 1987, 21 (04) :447-452
[9]   Single-nucleotide polymorphism in the human mu opioid receptor gene alters β-endorphin binding and activity:: Possible implications for opiate addiction [J].
Bond, C ;
LaForge, KS ;
Tian, MT ;
Melia, D ;
Zhang, SW ;
Borg, L ;
Gong, JH ;
Schluger, J ;
Strong, JA ;
Leal, SM ;
Tischfield, JA ;
Kreek, MJ ;
Yu, L .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (16) :9608-9613
[10]   Treating cocaine addiction:: From preclinical to clinical trial experience with γ-vinyl GABA [J].
Brodie, JD ;
Figueroa, E ;
Dewey, SL .
SYNAPSE, 2003, 50 (03) :261-265